Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:08:38 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:PTCT - PTC THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PTCT - Q0.124.71·24.800.224.72+0.030.142.71,01424124.61  25.065  24.6159.84  17.5309:47:55Apr 1115 min RT 2¢

Recent Trades - Last 10 of 241
Time ETExPriceChangeVolume
09:48:04Q24.720.03100
09:48:04Q24.7550.06550
09:48:04Q24.720.03100
09:47:55Q24.720.03100
09:47:55Q24.720.0337
09:47:46Q24.770.0850
09:47:30Q24.770.0863
09:47:15Q24.76240.07241
09:47:06Q24.770.0847
09:47:06Q24.770.08100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-11 08:00U:PTCTNews ReleasePTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
2024-03-28 08:30U:PTCTNews ReleasePTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
2024-03-19 07:30U:PTCTNews ReleasePTC Therapeutics Provides Key Regulatory Updates
2024-02-29 16:05U:PTCTNews ReleasePTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 17:20U:PTCTNews ReleasePTC Therapeutics to Participate at Upcoming Investor Conferences
2024-02-22 16:30U:PTCTNews ReleasePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-15 08:00U:PTCTNews ReleasePTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
2024-01-25 16:05U:PTCTNews ReleaseCHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna ¢ „ ¢ (ataluren) Following Re-examination Procedure
2024-01-08 09:26U:PTCTNews ReleasePTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 08:00U:PTCTNews ReleasePTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-14 16:30U:PTCTNews ReleasePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-05 16:15U:PTCTNews ReleasePTC Therapeutics Provides Updates on Translarna ¢ „ ¢ Regulatory Activities
2023-11-03 16:30U:PTCTNews ReleasePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-26 16:05U:PTCTNews ReleasePTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
2023-10-19 08:00U:PTCTNews ReleasePTC Therapeutics Announces Evrysdi ‚ ® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
2023-10-16 16:30U:PTCTNews ReleasePTC Therapeutics to Host Conference Call to Discuss ¢ € ¯Third Quarter 2023 Financial Results ¢ € ¯
2023-09-28 16:30U:PTCTNews ReleasePTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
2023-09-15 06:00U:PTCTNews ReleaseCHMP Delivers Opinion on Translarna ¢ „ ¢ for Conversion to Full Authorization
2023-09-12 08:00U:PTCTNews ReleaseSensorium Therapeutics Appoints Veteran Life Sciences Executive ‚  Mr. David Southwell to its Board of Directors
2023-09-07 08:00U:PTCTNews ReleasePTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community